Sept 11 (Reuters) - Moderna said on Monday it is collaborating with Immatics to develop cancer vaccines.
Immatics will get $120 million upfront cash as part of the agreement. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.3 USD | +0.26% | -1.26% | +26.03% |
May. 15 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
May. 14 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
Sept 11 (Reuters) - Moderna said on Monday it is collaborating with Immatics to develop cancer vaccines.
Immatics will get $120 million upfront cash as part of the agreement. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
147.6 USD | -0.55% | -4.80% | 56.87B | ||
13.3 USD | +0.26% | -1.26% | 1.37B | ||
1st Jan change | Capi. | |
---|---|---|
+26.03% | 1.37B | |
+17.05% | 124B | |
+15.93% | 109B | |
-6.91% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-7.15% | 16.61B | |
-37.63% | 16.43B | |
+1.99% | 13.4B | |
+24.85% | 11.47B |